Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 17, 2025 09:37 ET | Source: Spherix Global Insights

Diverging Treatment Goals Emerge Between Hematologists and Nephrologists in aHUS Care, According to Spherix Global Insights

EXTON, PA, July 17, 2025 (GLOBE NEWSWIRE) -- In the latest Special Topix™: Co-Management Approaches in aHUS (US), Spherix Global Insights explores the nuanced dynamics between hematologists and...
July 08, 2025 14:22 ET | Source: Spherix Global Insights

Market Barriers Continue to Challenge PNH Treatment Optimization Despite Emerging Options, According to Spherix Global Insights

EXTON, PA, July 08, 2025 (GLOBE NEWSWIRE) -- Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic blood disorder that can affect individuals of any age, race, or gender, though it is most...
April 08, 2025 10:53 ET | Source: Spherix Global Insights

Emerging IgAN Therapies Bring Hope – But Patients Still Face Emotional and Financial Barriers, According to Spherix Global Insights

EXTON, PA, April 08, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights has released the first edition of its new Patient Dynamix™: IgA Nephropathy (US) series, delivering a comprehensive look at the...
March 26, 2025 13:35 ET | Source: Spherix Global Insights

Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and Novartis Continue to Gain Traction, According to Spherix Global Insights

EXTON, PA, March 26, 2025 (GLOBE NEWSWIRE) -- Nearly all nephrologists agree that early and aggressive intervention is essential for improving outcomes in IgA nephropathy (IgAN). However, findings...
March 18, 2025 12:09 ET | Source: Spherix Global Insights

Fabhalta Shakes Up the PNH Market in 15 Months as Soliris, Ultomiris, and Empaveli Compete and Voydeya and PiaSky Carve Their Niche

EXTON, PA, March 18, 2025 (GLOBE NEWSWIRE) -- Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and debilitating blood disorder that affects approximately 8,000 to 10,000 people in North America...
June 26, 2024 04:00 ET | Source: Spherix Global Insights

As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Continued Unmet Needs and Track New Launches

EXTON, PA, June 26, 2024 (GLOBE NEWSWIRE) -- Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder in which red blood cells prematurely break apart, a process known as hemolysis....
June 13, 2024 11:39 ET | Source: Spherix Global Insights

Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment

EXTON, PA, June 13, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare kidney disease that presents significant challenges for both patients and nephrologists. Currently, there are...